Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2887-2897

  Nishizaki, M ^a   Meyn, R E ^a   Levy, L B ^a   Atkinson, E N ^a   White, R A ^a   Roth, J A ^a   Ji, L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; RADIOTHERAPY; TAXOIDS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034814353     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Cancer statistics
2. Novel approaches to locally advanced unresectable non-small cell lung cancer
3. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue
4. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
5. New agents in the treatment of small cell lung cancer
6. Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer
7. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer
8. Overview of current and future chemotherapeutic agents in non-small cell lung cancer
9. Docetaxel (Taxotere), and gemcitabine in combination therapy
10. Role of taxanes in lung-cancer chemotherapy
11. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
12. Taxanes in combined-modality therapy for solid tumors
13. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
14. Docetaxel enhances tumor radioresponse in vivo
15. Phase I study of docetaxel with concomitant thoracic radiation therapy
16. p53, the cellular gatekeeper for growth and division
17. Cancer therapy and p53
18. p53 functions and dysfunction
19. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
20. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
21. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
22. Gene therapy for non-small cell lung cancer: A preliminary report of a Phase I trial of adenoviral p53 gene replacement
23. Restoration of p53 gene function for cancer treatment
24. The current status of cancer gene therapy trials
25. Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer
26. Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene
27. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells
28. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
29. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
30. Manipulation of adenovirus vectors
31. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression
32. TP53 tumour suppressor gene - Clues to molecular carcinogenesis and cancer therapy
33. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT
34. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo
35. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
36. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
37. Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions
38. The search for synergy: A critical review from a response surface perspective
39. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines
40. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer - A meta-analysis
41. Chemotherapy for advanced non-small cell lung cancer: Past, present, and future
42. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer
43. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines
44. Drug-target interactions: Only the first step in the commitment to a programmed cell death?
45. Apoptosis and chemotherapy resistance
46. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
47. p53 is required for radiation-induced apoptosis in mouse thymocytes
48. p53 status and the efficacy of cancer therapy in vivo